POLARITYTE, INC. (NASDAQ:COOL) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On May 6, 2019, PolarityTE, Inc. (“PolarityTE”) closed on the full exercise of the option to purchase an additional 445,945 shares of PolarityTE’s common stock granted to the underwriters as part of an underwritten public offering of an aggregate of 3,418,918 shares of PolarityTE’s common stock. PolarityTE previously issued and sold 2,972,973 shares of common stock on April 12, 2019. Cantor Fitzgerald & Co. acted as the sole book-running manager for the offering.
The net proceeds of the offering are estimated to be approximately $28.7 million, after deducting estimated offering expenses payable by PolarityTE. PolarityTE intends to use the net proceeds from the offering for research, development and manufacturing of its products and product candidates, efforts toward commercialization and required registration or approval of its products and product candidates with applicable regulatory authorities, and for other general corporate purposes.
The securities described above were offered by PolarityTE to a registration statement (File No. 333-229584), which has been filed with and declared effective by the Securities and Exchange Commission (“SEC”). A prospectus supplement and accompanying prospectus relating to this offering has been filed with the SEC. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 6th Floor, New York, NY 10022 or by e-mail at [email protected]
About POLARITYTE, INC. (NASDAQ:COOL)
PolarityTE, Inc., formerly Majesco Entertainment Company, is a technology company. The Company has developed, marketed, published and distributed software through online platforms. The Company develops applications for gaming on computers, handheld devices and game consoles. The Company is the owner of patent applications and know-how related to regenerative medicine and tissue engineering, as well as software applications used in diagnosis and treatment related to regenerative medicine. It seeks to develop and obtain regulatory approval for technology that will utilize a patient’s own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. Its PolarityTE platform simplifies regeneration and allows cells to function naturally. The platform can be applied across all cells, tissues and composite structures. Its platform induces cell and tissue polarity, and creates functional tissue that mirrors natural development in the human body.